The use of PET imaging in studying cognition, genetics and pharmacotherapeutic interventions in schizophrenia. (January 2011)

• Record Type: Journal Article
• Authors: Vyas, Nora S; Patel, Neva H; Nijran, Kuldip S; Al-Nahhas, Adil; Puri, Basant K
• Is Part Of: Expert review of neurotherapeutics. Volume 11:Number 1(2011)
• Page Start: 37
• Page End: 51
• Publication Date: 2011-01
• Subjects: antipsychotics -- cognition -- COMT -- dopamine receptors -- memory -- PET -- prefrontal cortex -- schizophrenia -- serotonin; Neuropharmacology -- Periodicals; 615.7805
• DOI: 10.1586/ern.10.160
• Languages: English
• ISSNs: 1473-7175

Abstract

Positron emission tomography (PET) offers a strategic imaging platform to provide a map of functional neural correlates associated with the underlying cognitive deficits in schizophrenia. It enables regional cerebral glucose metabolism and dopaminergic and serotonergic receptor function to be studied. PET neuroimaging can therefore be used in drug development and to study putative treatments. Recent PET studies of the first-generation antipsychotics flupentixol and haloperidol, and of the second-generation antipsychotics risperidone, aripiprazole, quetiapine, sertindole, ziprasidone, paliperidone and olanzapine, have been carried out; modulation of limbic circuitry has been found to be a predictor of treatment response. PET can also be used to predict and monitor likely extrapyramidal side effects from antipsychotic treatment. PET and neuropsychological testing can together also allow the study of putative molecular genetic changes associated with schizophrenia. Advances in the imaging, cognition and molecular genetics are likely to lead to the development of future diagnostics, treatments and novel pharmacological agents.